FIELD OF INVENTION
[001] The present disclosure broadly relates to the field of biopharmaceuticals and particularly refers to a composition exhibiting anti-biofilm formation activity against the opportunistic human pathogens. The present disclosure also discloses a process of preparing the composition.
BACKGROUND OF INVENTION
[002] A biofilm is a three-dimensional community of sessile, stably attached microorganisms, especially bacteria, embedded in a self-produced hydrated matrix of extracellular polymeric substances. The growth properties of such bacteria are different from those of planktonic, free-living microorganisms. Microbial biofilms develop when microorganisms irreversibly adhere to a surface and produce extracellular polymers that facilitate the adhesion and provide a structural matrix. Bacteria in the biofilm state have been shown to be 10-10,000-fold less susceptible to antibiotic treatment. Bacterial cells living in the biofilm exhibit a peculiar behavior of synchronized virulence gene expression and many enzymes present in the biofilm matrix are reported to cleave the antibiotics. Besides, the slimy and mucous nature of biofilm, blocks the penetration of the antibiotics. Altogether, bacterial cells residing in the biofilm develop resistance to the antibiotics than their planktonic counterparts. Consequently, biofilm formation is often responsible for chronic infections due to bacterial persistence despite various antibiotic treatments available in the market.
[003] Biofilm forming ability of Methicillin-Resistant Staphylococcus aureus (MRSA) makes it very strong and stubborn. Biofilms are related to medical and industrial significance because of their tendency to get accumulated on varied substrates and their resistance to antimicrobial agents and detergents. They have given rise to significant public health problems as biofilm-associated microorganisms have different behaviour from planktonic organisms in aspects of growth rates and their resistance to the microbial treatments. Several cases

related to chronic infections, that are difficult or impossible to eliminate with
conventional antibiotic therapies, are known to involve biofilms.
[004] Therefore, biofilm has become the target for the development of new
compositions for inhibition, prevention, and removal of microbial infections, as
they are believed to be partly responsible for increasing the rates of antibiotic
resistance.
[005] In recent years, various antibiofilm agents in combination with the
antibiotics are reported to potentiate the efficacy of the antibiotics against the
biofilm formed by MRS A. For instance, the patent Document US 10420822
discloses the use of disaccharide trehalose and gentamicin for anti-biofilm
property. In another patent Document EP2117611B1, a bismuth thiol containing
bioremodelable wound dressing based on biofilm inhibition is disclosed. A
gallium containing composition is disclosed in EP1691614B1 for inhibition of
biofilms.
[006] Although the currently available antibiofilm agents are able to show
some amount of antibiofilm activity, however, the treatment strategies with
antibiofilm agents in combination with the antibiotics against MRSA infections
are ineffective because of the emergence of the antibiotic resistance.
Accordingly, there is a dire need for the development of the composition based
on the natural compounds which have no side effects and devoid of the antibiotic
resistance.
SUMMARY OF THE INVENTION
[007] In an aspect of the present disclosure, there is provided a composition comprising: a) dodecanolide; and b) citral, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition.
[008] In another aspect of the present disclosure, there is provided a process for preparing the composition comprising: a) dodecanolide; b) citral; (c) at least one water phase component; and (d) at least one oil phase component, wherein

dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition, said process comprising: i) obtaining dodecanolide; ii) obtaining citral; and iii) obtaining at least one water phase component or at least one oil phase component; iv) contacting dodecanolide and citral with the at least one water phase component or the at least one oil phase component to obtain the composition.
[009] In yet another aspect of the present disclosure, there is provided a process for preparing the composition comprising: a) dodecanolide; and b) citral, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition, said process comprising: i) heating the at least one water phase component to a temperature in range of 65-75°C for a time period in a range of 25-35 minutes, to obtain a heated water phase component, and blending the heated water phase component at a speed in a range of 200-400 rpm for a time period in a range of 10-20 minutes to obtain a first mixture; ii) heating the at least one oil phase component at a temperature in a range of 60-80°C for a time period in a range of 25-35 minutes to obtain, to obtain a heated oil phase component, and blending the heated oil phase component at a speed of 300-500 rpm for a time period in a range of 20-40 minutes to obtain a second mixture; iii) contacting the first mixture and the second mixture at a speed in a range of 400-600 rpm for a time period in range of 2-40 minutes to obtain the third mixture; and iv) contacting dodecanolide, citral, the at least one solvent and the third mixture at a speed in a range of 400-600 rpm for a time period in a range of 40-50 minutes at a temperature in a range of 35-40°C, to obtain the composition.
[0010] These and other features, aspects, and advantages of the present subject matter will be better understood with reference to the following description and appended claims. This summary is provided to introduce a selection of concepts in a simplified form. This summary is not intended to identify key features or

essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.
BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS
[0011] The following drawings form a part of the present specification and are
included to further illustrate aspects of the present disclosure. The disclosure may
be better understood by reference to the drawings in combination with the detailed
description of the specific embodiments presented herein.
[0012] Figure 1 depicts the percentage inhibition of biofilm formed by
Methicillin-Resistant Staphylococcus aureus (MRSA) in the presence of
dodecanolide at different concentrations, in accordance with an embodiment of
the present disclosure.
[0013] Figure 2 depicts the percentage inhibition of biofilm formed by MRS A in
the presence of citral at different concentrations, in accordance with an
embodiment of the present disclosure.
[0014] Figure 3 depicts the various combinations of dodecanolide and citral
used at different concentrations, in accordance with an embodiment of the present
disclosure.
[0015] Figure 4 depicts the representative images of petriplates of Colony
Forming Unit (CFU) assay for the assessment of non-antibacterial activity against
MRS A, in accordance with an embodiment of the present disclosure.
[0016] Figure 5 depicts the assessment of growth of MRSA upon treatment with
compositions CI and C2, in accordance with an embodiment of the present
disclosure.
[0017] Figure 6 depicts the effect of C2 on pre-formed MRSA biofilm, in
accordance with an embodiment of the present disclosure.
[0018] Figure 7 depicts the biofilm eradicating ability of rifampicin potentiated
by C2 as observed under confocal laser scanning microscope (CLSM), in
accordance with an embodiment of the present disclosure.
DETAILED DESCRIPTION OF THE INVENTION

[0019] Those skilled in the art will be aware that the present disclosure is subject
to variations and modifications other than those specifically described. It is to be
understood that the present disclosure includes all such variations and
modifications. The disclosure also includes all such steps, features,
compositions, and compounds referred to or indicated in this specification,
individually or collectively, and any and all combinations of any or more of such
steps or features.
Definitions
[0020] For convenience, before further description of the present disclosure,
certain terms employed in the specification, and examples are delineated here.
These definitions should be read in the light of the remainder of the disclosure
and understood as by a person of skill in the art. The terms used herein have the
meanings recognized and known to those of skill in the art, however, for
convenience and completeness, particular terms and their meanings are set forth
below.
[0021] The articles "a", "an" and "the" are used to refer to one or to more than
one (i.e., to at least one) of the grammatical object of the article.
[0022] The terms "comprise" and "comprising" are used in the inclusive, open
sense, meaning that additional elements may be included. It is not intended to be
construed as "consists of only".
[0023] Throughout this specification, unless the context requires otherwise the
word "comprise", and variations such as "comprises" and "comprising", will be
understood to imply the inclusion of a stated element or step or group of element
or steps but not the exclusion of any other element or step or group of element or
steps.
[0024] The term "including" is used to mean "including but not limited to".
"Including" and "including but not limited to" are used interchangeably.
[0025] Phytochemicals (from Greek phyto, meaning "plant") are chemicals
produced by plants through primary or secondary metabolism. They generally
have biological activity in the plant host and play a role in plant growth or
defenses against competitors, pathogens, or predators.

[0026] The term "biofilm" is used to describe the aggregation of microorganisms in which cells adhere to each other to a surface (living/nonliving). The biofilm formation confers numerous advantages to the pathogens, including increase in drug resistance and providing high tolerance to environmental stresses such as antimicrobials and host immune responses. [0027] As used herein, the term water-phase component and oil-phase component are collectively present as water in oil base components that are added to the active ingredients, forming the composition as disclosed in the present disclosure. Particularly, the water phase components are defined as components that dissolve in water. Similarly, oil phase components are defined as components that dissolve in oil.
[0028] For the purpose of the present disclosure, the term "preservatives", "humectants", "chelants", "feel enhancer", "neutralizers", "emollients", "structurants" refers to the generally known components used in the art. [0029] The Biofilm Inhibitory Concentration (BIC) is defined as the lower concentration of antibiotics/ antimicrobials showing 50% and 90% reduction of biofilm binding. The percentage of biofilm inhibition is calculated by the following formula:
r,/r.- «■■! i i -i ... rAbsorbance of Control-Absorbance of Treated-, ,, __
% Biofilm Inhibition = f 1 x 100
k Absorbance of Control J
[0030] For the purposes of the present disclosure, the term "synergism" is used to describe the interaction or cooperation of two or more organizations, substances, or other agents to produce a combined effect greater than the sum of their separate effects. The synergistic effect shown by the combination of two phytochemicals at various concentrations is studied by checker board assay through Fractional Inhibitory Concentration Index (FIC). Therefore, FIC is used to estimate the interaction between two or more phytochemicals used in combination.
i) If the FIC index is <0.5, then the combination effect shown by the
two or more phytochemicals used in combination is denoted as
synergistic.

ii) If the FIC index is between 0.5 to 4.0, then no interaction is shown by
two or more phytochemicals used in combination, iii) If the FIC index is >4.0, then the combination effect shown by the two or more phytochemicals used in combination is denoted as antagonistic. [0031] Ratios, concentrations, amounts, and other numerical data may be presented herein in a range format. It is to be understood that such range format is used merely for convenience and brevity and should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited.
[0032] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the disclosure, the preferred methods, and materials are now described. All publications mentioned herein are incorporated herein by reference. [0033] The present disclosure is not to be limited in scope by the specific embodiments described herein, which are intended for the purposes of exemplification only. Functionally-equivalent products, compositions, and methods are clearly within the scope of the disclosure, as described herein. [0034] As discussed in the background of the present disclosure, many currently available antibiotics are reported to have toxic side effects. Targeting biofilm formation has become an alternative strategy to the antibiotics. Different anti-biofilm agents that are available in the art are also associated with a risk of antibiotic resistance development. Many compounds with anti-biofilm activity have been identified from various natural resources so far {Int. J. Pharm. Sci. Res., 2012, 4, 282-285). But still many of the identified compounds have failed to cross the clinical trials because of the requirement of high concentration and toxic side effects. Therefore, a new avenue for combating antibiotic resistance

can be provided by the treatment including co-dosing of antibiotics and natural compounds disrupting biofilm formation.
[0035] In the present invention, a synergistic combination of phytochemicals is developed that provides the benefits of reduced toxicity, improved efficacy and impedes the pathogen in developing the resistance against two drug candidates concurrently. The current invention is also aimed to potentiate the efficacy of the available antibiotics by combining with the phytochemicals and the context of excluding the development of drug resistance is also considered. Therefore, the current invention focuses on the development of cost-effective, non-toxic, and potential anti-biofilm composition based on natural compounds. [0036] The present disclosure pertains to the synergistic combination achieved through the use of phytochemicals comprising of dodecanolide and citral as mentioned herein. Dodecanolide and citral are regarded as Generally Recognized As Safe (GRAS) compound which is approved by Food and Drug Administration. It is specified that the present disclosure provides a composition comprising: a) dodecanolide; and b) citral, wherein dodecanolide has a weight percentage in a range of 0.0001-0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015-0.004% with respect to the composition. The composition exhibits synergistic inhibitory activity against the biofilm formation in species of Methicillin-Resistant Staphylococcus aureus. Besides, the synergistic combination of dodecanolide and citral exhibits anti-biofilm efficacy at lower concentrations with a decreased probability of developing drug resistance.
[0037] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; and b) citral, wherein dodecanolide has a weight percentage in a range of 0.0001-0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015-0.004% with respect to the composition.
[0038] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; and b) citral, wherein dodecanolide has a weight percentage in a range of 0.0007-0.004 % with respect to the

composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition. In another embodiment of the present disclosure, dodecanolide has a weight percentage in a range of 0.001-0.003 % with respect to the composition. In yet another embodiment of the present disclosure, dodecanolide has a weight percentage of 0.0014-0.0028 % with respect to the composition.
[0039] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; and b) citral, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of .0017-0.0037 % with respect to the composition. In another embodiment of the present disclosure, citral has a weight percentage in a range of 0.0011-0.0029 % with respect to the composition.
[0040] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; b) citral; and c) at least one water phase component, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition. [0041] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; b) citral; and c) at least one oil phase component, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition. [0042] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; b) citral; and c) a combination of at least one water phase component and at least one oil phase component, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition.
[0043] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; b) citral; and c) at least one water

phase component, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition, and wherein the at least one water phase component is selected from a group consisting of preservatives, humectants, chelants, and combinations thereof. In another embodiment of the present disclosure, the preservatives are selected from a group consisting of paraben, gluconolactone, sodium benzoate, chlorobutanol, benzyl alcohol, imidazolidinyl urea, benzalkonium chloride, alpha tocopherol, sodium sulphite, methyl-dibromo glutaronitrile, tea tree essential oil, and combinations thereof, the humectants are selected from a group consisting of aloe vera powder, arnica extract, algae extract, hydrolyzed baobab protein, coenzyme qlO, hydrolyzed collagen protein, colloidal oatmeal, glycerin, caprylyl glycol, ceramide complex, lacto-ceramide, matrixyl s-6, propylene glycol, rhubarb root extract, hyaluronic acid, hydrolyzed jojoba protein, hydrolyzed keratin protein, sodium PCA, and combinations thereof, the chelants are selected from a group consisting of diethylenetriaminepentaacetic acid, tetrasodium ethylenediaminetetraacetate, disodium ethylenediaminetetraacetate, triglycollamic acid, ethane 1-hydroxy-1, 1-diphosphonate, polyphosphates, citric acid, and combinations thereof.
[0044] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; b) citral; c) at least one oil phase component, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition, and wherein the at least one oil phase component is selected from a group consisting of feel enhancers, neutralizers, emollients, structurants, and combinations thereof. In another embodiment of the present disclosure, the feel enhancers are selected from a group consisting of isopropyl myristate, bis-diglyceryl polyacyladipate-1, butylene glycol dicaprylate/dicaprate, cetearyl isononanoate, decyl oleate, glyceryl oleate, glyceryl ricinoleate, oleyl erucate, olus oil, alkyl citrate and stearate esters, waxes, essential oils, and combinations thereof, the neutralizers

are selected from a group consisting of borax, sodium hydroxide, sodium carbonate and alkali extract of coconut husk, triethanol amine, and combinations thereof, the emollients are selected from a group consisting of amodimethicone, C12-15 alkyl benzoate, cetyl palmitate, isopropyl myristate, jojoba gel, mineral oil, natural gel-wax, octyldodecanol, amodimethicone, cyclodimethicone, cyclomethicone, dimethicone 500, dimethicone satin, isodimethicone copolymer, PEG8, polyisobutene 250, squalane, almond oil, castor oil, grapeseed oil, red raspberry seed oil, cherry kernel oil, and combinations thereof, and the structurants are selected from a group consisting of rice bran oil, corn oil, sunflower oil, starch, alginate, carnauba wax, bees wax, berry wax, fruit wax, silicone based polymers, acrylate copolymer, cellulose based polymers, and combinations thereof.
[0045] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; b) citral; and c) at least one water phase component, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition, and wherein the at least one water phase component is selected from a group consisting of preservatives, humectants, chelants, and combinations thereof, and wherein the preservatives has a weight percentage in a range of 0.005-0.5% with respect to the composition, humectants has a weight percentage in a range of 0.01-10% with respect to the composition, chelants has a weight percentage in a range of 0.01-0.5%) with respect to the composition. In another embodiment of the present disclosure, the preservatives has a weight percentage in a range of 0.005 - 0.3 %> with respect to the composition, humectants has a weight percentage in a range of 2 - 6 %> with respect to the composition, and chelants has a weight percentage in a range of 0.1 - 0.3 %> with respect to the composition.
[0046] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; b) citral; and c) at least one oil phase component, wherein dodecanolide has a weight percentage in a range of 0.0001

- 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition, and wherein the at least one oil phase component is selected from a group consisting of feel enhancers, neutralizers, emollients, and structurants, and combinations thereof, wherein the feel enhancers has a weight percentage in range of 0.01-25% with respect to the composition, the neutralizers has a weight percentage in a range of 0.0004-0.4% with respect to the composition, the emollients has a weight percentage in a range of 0.05-20%) with respect to the composition, and the structurants has a weight percentage in a range of 0.01-7% with respect to the composition. In another embodiment of the present disclosure, the feel enhancers has a weight percentage in range of 5 - 10 % with respect to the composition, neutralizers has a weight percentage in a range of 0.1 - 0.3 % with respect to the composition, emollients has a weight percentage in a range of 5 -10 % with respect to the composition, and structurants has a weight percentage in a range of 0.1 - 3 % with respect to the composition.
[0047] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; b) citral; and c) a combination of at least one water phase and at least one oil phase component, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition.
[0048] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; and b) citral, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition, and wherein the composition exhibits inhibitory activity against biofilm formation.
[0049] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; b) citral; and c) at least one water phase component, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight

percentage in a range of 0.0015 - 0.004 % with respect to the composition, and wherein the least one water phase component is selected from a group consisting of preservatives, humectants, chelants, and combinations thereof, and wherein the composition exhibits inhibitory activity against biofilm formation. [0050] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; b) citral; and c) at least one oil phase component, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition, wherein the at least one oil phase component is selected from a group consisting of feel enhancers, neutralizers, emollients, structurants, and combinations thereof, and wherein the composition exhibits inhibitory activity against biofilm formation. [0051] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; b) citral; and c) a combination of at least one water phase and at least oil phase component, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition, and wherein the at least one water phase is selected from a group consisting of preservatives, humectants, chelants, and combinations thereof, and the at least one oil phase component is selected from a group consisting of feel enhancers, neutralizers, emollients, structurants, and combinations thereof, and wherein the composition exhibits inhibitory activity against biofilm formation.
[0052] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; and b) citral, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition, and wherein the composition exhibits inhibitory activity against biofilm formation and wherein the biofilm formation is formed by Staphylococcus aureus.

[0053] In an embodiment of the present disclosure, there is provided a composition comprising: a) dodecanolide; and b) citral, wherein dodecanolide has a weight percentage in a range of 0.0001 - 0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015 - 0.004 % with respect to the composition, and wherein the composition is effective for a period of 12 months to 26 months.
[0054] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: a) dodecanolide; and b) citral, wherein dodecanolide has a weight percentage in a range of 0.0001-0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015-0.004% with respect to the composition, said process comprising: a) obtaining dodecanolide; b) obtaining citral; c) obtaining at least one water phase component or at least one oil phase component; and d) contacting dodecanolide and citral with the at least one water phase component or the at least one oil phase component to obtain the composition.
[0055] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: a) dodecanolide; b) citral; and c) at least one water phase component or the at least one oil phase component, wherein dodecanolide has a weight percentage in a range of 0.0001-0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015-0.004% with respect to the composition, said process comprising: a) obtaining dodecanolide; b) obtaining citral; c) obtaining at least one water phase component or at least one oil phase component; and d) contacting dodecanolide and citral with the at least one water phase component or the at least one oil phase component to obtain the composition, wherein the at least one water phase component is selected from a group consisting of preservatives, humectants, chelants, and combinations thereof and wherein the at least one oil phase component is selected from a group consisting of feel enhancers, neutralizers, emollients, structurants, and combinations thereof.
[0056] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: a) dodecanolide; b) citral; and c) at

least one water phase component or the at least one oil phase component, wherein dodecanolide has a weight percentage in a range of 0.0001-0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015-0.004% with respect to the composition, said process comprising: a) obtaining dodecanolide; b) obtaining citral; c) obtaining at least one water phase component or at least one oil phase component; and d) contacting dodecanolide and citral with the at least one water phase component or the at least one oil phase component to obtain the composition, wherein the at least one oil phase component is selected from feel enhancers having a weight percentage in range of 0.01-25% with respect to the composition, neutralizers having a weight percentage in a range of 0.0004-0.4%) with respect to the composition, emollients having a weight percentage in a range of 0.05-20%) with respect to the composition, and structurants having a weight percentage in a range of 0.01-7%) with respect to the composition.
[0057] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: a) dodecanolide; b) citral; and c) at least one water phase component or at least one oil phase component, wherein dodecanolide has a weight percentage in a range of 0.0001-0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015-0.004%) with respect to the composition, said process comprising: i) obtaining dodecanolide; ii) obtaining citral; iii) obtaining at least one water phase component or at least one oil phase component; and iv) contacting dodecanolide and citral with the at least one water phase component or the at least one oil phase component to obtain the composition, wherein the process further comprises at least one solvent having a weight percentage in a range of 10-98%> with respect to the composition.
[0058] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: a) dodecanolide; b) citral; and c) at least one water phase component or at least one oil phase component, wherein dodecanolide has a weight percentage in a range of 0.0001-0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015-

0.004% with respect to the composition, said process comprising: i) obtaining dodecanolide; ii) obtaining citral; iii) obtaining at least one water phase component or at least one oil phase component; and iv) contacting dodecanolide and citral with the at least one water phase component or the at least one oil phase component to obtain the composition, wherein the process further comprises at least one solvent selected from a group consisting of water, methanol, ethanol, dimethyl sulfoxide (DMSO), and combinations thereof having a weight percentage in a range of 10-98% with respect to the composition.
[0059] In an embodiment of the present disclosure, there is provided a process for preparing the composition comprising: a) dodecanolide; and b) citral, wherein dodecanolide has a weight percentage in a range of 0.0001-0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015-0.004%) with respect to the composition, said process comprising: i) heating the at least one water phase component to a temperature in range of 65-75°C for a time period in a range of 25-35 minutes, to obtain a heated water phase component, and blending the heated water phase component at a speed in a range of 200-400 rpm for a time period in a range of 10-20 minutes to obtain a first mixture; ii) heating the at least one oil phase component at a temperature in a range of 60-80°C for a time period in a range of 25-35 minutes to obtain, to obtain a heated oil phase component, and blending the heated oil phase component at a speed of 300-500 rpm for a time period in a range of 20-40 minutes to obtain a second mixture; iii) contacting the first mixture and the second mixture at a speed in a range of 400-600 rpm for a time period in range of 2-40 minutes to obtain the third mixture; and iv) contacting dodecanolide, citral, the at least one solvent and the third mixture at a speed in a range of 400-600 rpm for a time period in a range of 40-50 minutes at a temperature in a range of 35-40°C, to obtain the composition.
[0060] In an embodiment of the present disclosure, there is provided a formulation comprising the composition as described herein, wherein the

formulation can be used in a form of an anti-biofilm cream, ointment, lotion, paste, gel or the like.
[0061] Although the subject matter has been described in considerable detail with reference to certain examples and implementations thereof, other implementations are possible. EXAMPLES
[0062] The disclosure will now be illustrated with working examples, which is intended to illustrate the working of disclosure and not intended to take restrictively to imply any limitations on the scope of the present disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice of the disclosed methods and compositions, the exemplary methods, devices and materials are described herein. It is to be understood that this disclosure is not limited to particular methods, and experimental conditions described, as such methods and conditions may apply.
[0063] The working examples as depicted in the forthcoming sections highlight the combinatorial effect of different phytochemicals used at different concentrations in the composition against the species of Methicillin Resistant Staphylococcus aureus (MRSA). The composition as disclosed in the present disclosure comprised: a) dodecanolide; and b) citral, wherein dodecanolide has a weight percentage in a range of 0.0001-0.005 % with respect to the composition, and citral has a weight percentage in a range of 0.0015-0.004% with respect to the composition. The composition exhibited synergistic effect on the inhibitory activity against the biofilm formation by different species of MRSA. The synergism between dodecanolide and citral was achieved when the combinatorial effect is greater than the sum of the individual phytochemical effect exhibited by each component against the biofilm by MRSA. The absence of any of the phytochemical specified above or replacement of the same with

any other phytochemical substantially diminished the synergistic effect against the biofilm formation by MRSA.
Materials and Methods
[0064] The phytochemicals such as dodecanolide and citral were used for arriving at the composition of the present disclosure. Dodecanolide and citral were procured from Sigma-Aldrich and Alfa-Aesar, respectively. The antibiofilm efficacy of the phytochemicals mentioned above was studied against MRSA species forming a biofilm.
Evaluation of biofilm inhibitory concentration (BIC) of dodecanolide and citral against biofilm formed by Methicillin-Resistant S. aureus (MRSA): [0065] Different concentrations of dodecanolide and citral were used against MRSA. The effect of dodecanolide and citral on biofilm formed by MRSA at different concentrations was evaluated to determine the Biofilm Inhibitory Concentration (BIC) of the respective drug. The BIC of dodecanolide and citral against MRSA biofilm was evaluated by broth dilution assay in 24 well Microtitre Plates (MTP). For this purpose, each well of MTP was loaded with 1 mL of Typtone soya broth containing 1% of sucrose (TSBS). 1% (v/v) of 12 h MRSA culture was used to inoculate each well, and was incubated at 37° C for 24 h. MRSA was allowed to form biofilm on 24 well Micro Titer Plate (MTP) treated with Dodecanolide at concentrations: 225, 112.5, 56.25, 28.125 and 14.0625 ug mL"1 and Citral at concentrations: 100, 50, 25, 12.5 and 6.25 ug mL" 1. TSBS with MRSA culture alone was maintained as control. After incubation, the loosely bound planktonic cells were removed and the biofilm attached with MTP plate was washed twice with sterile saline and was air dried. Then, 0.4 % of crystal violet was added to each well and incubated for 5 min at room temperature, again washed and air dried. Subsequently, the biofilms were destained using 10 % glacial acetic acid. The absorbance of the control and treated wells were measured at 570 nm. The percentage of biofilm inhibition was calculated using the formula:

[0066] Checkerboard assay - Checkerboard assay was used for studying the effect of the potency of the combination of phytochemicals in comparison to the effect of the potency of the individual phytochemicals against the biofilm formed by the species of MRS A. The effect of the potency of the combination of phytochemicals in comparison to the effect of the potency of individual phytochemical was determined by Fractional Inhibitory Concentration (FIC) index. The phytochemical combinatorial effect was defined by the FIC index value.
• If FIC index is <0.5, then the phytochemical combinatorial effect is denoted as synergistic effect.
• If FIC index is between 0.5 to 4.0, then the phytochemical combinatorial effect is indifferent.
• If FIC index is >4.0, then the phytochemical combinatorial effect is denoted as antagonistic effect.
[0067] In the present disclosure, the combinatorial effect of dodecanolide and citral was evaluated by using Checkerboard assay. Dodecanolide and citral were used in a combination to inhibit the biofilm formed by MRSA. To study the effectiveness of the combination of the phytochemicals used against the species of MRSA, FIC index value was determined to describe the combinatorial effect of dodecanolide and citral against biofilm formed by MRSA. The FIC index was determined as prescribed by ODDs, 2003 as follows:

Example 1
(a) Effect of dodecanolide on MRSA
[0068] The effect of dodecanolide against the biofilm formed by MRSA was studied by using varying concentrations of dodecanolide, individually. The effect of dodecanolide on MRSA was studied by using dodecanolide at different concentrations ranging from 0 to 250 ug mL"1. The biofilm structure formed by MRSA was inhibited in a concentration dependent manner without inhibiting the growth of the MRSA species. It was observed that the biofilm structure formed by MRSA was inhibited by using various concentrations of dodecanolide. The results obtained have been depicted in Figure 1. Figure 1 illustrates the percentage inhibition of biofilm formed by MRSA in the presence of dodecanolide at different concentrations. It can be observed from Figure 1 that dodecanolide showed maximum inhibition of MRSA biofilm at a concentration of 225 ugmL"1.
(b) Effect of citral on MRSA
[0069] The effect of citral on MRSA was studied by using varying concentrations of citral, individually. Particularly, by using the various concentrations of citral, the biofilm formed by MRSA was inhibited. The effect of citral on MRSA was studied by using citral at different concentrations ranging from 0 to 200 ug mL"1. The results obtained have been depicted in Figure 2. Figure 2 illustrates the percentage inhibition of biofilm formed by MRSA in the presence of citral at different concentrations. As can be observed from Figure 2, the formation of MRSA biofilm was inhibited by using citral at a concentration of 100 ugmL"1.
[0070] Hence, it can be inferred from Figure 1 and 2 that BIC of dodecanolide and citral was determined at 225 ug mL"1 and 100 ug mL"1, respectively. Example 2
Effect of composition of the present disclosure on MRSA biofilm formation [0071] Various combinations of dodecanolide and citral were used against the biofilm formation by MRSA. The combinatorial effect of dodecanolide and citral against biofilm formed by MRSA was evaluated by the checkerboard assay

(as explained in Example 1). Figure 3 illustrates that various combinations of dodecanolide and citral were evaluated at different concentrations to arrive at the composition of the present disclosure. This layout of the combination of the aforementioned phytochemicals was followed for MRSA biofilm inhibition study. It can be deduced from the checkerboard assay that if the combinatorial effect of two phytochemicals is found to be greater than the sum of individual effect, then there is a synergistic effect between the two phytochemicals. However, the inverse of the synergistic effect is antagonistic effect, and the intermediate between two effects is indifferent.
(a) Evaluation of the composition on the biofilm formation by MRSA: [0072] Combinations of components such as dodecanolide and citral at different concentrations were utilized to assess their antibiofilm activity against MRSA, and their activity was evaluated by using checkerboard assay. In the combinations of dodecanolide and citral, dodecanolide was varied from 14.0625 to 225 ug ml/1 and citral was varied from 6.25 to 100 ug mL"1. Table 1 depicts the FIC indexes of dodecanolide and citral at varied concentrations against MRSA biofilm. As depicted in Table 1, the sign '*' indicated the presence and '-' indicated the absence of antibiofilm activity in individual and combination of phytochemicals, respectively.

[0073] From Table 1, it can be inferred that most of the combinations of dodecanolide and citral showed antibiofilm activity, however, only two combinations of dodecanolide and citral at 14.0625+25 ug mL"1 (CI) and 28.125+25 ug mL"1 (C2) depicted the synergistic effect on inhibiting the biofilm activity of MRSA with FIC indices of 0.3125 and 0.375, respectively (Both having FIC indices of <0.5). So, it can be deduced that dodecanolide and citral in combination CI with concentration of 14.0625+25 ug mL"1 demonstrated the maximum synergistic effect as it showed the lowest FIC index of 0.3125 amongst all the other combinations. It can also be inferred that the weight percentages of the dodecanolide and citral that exhibited anti-biofilm activity against MRSA biofilm were in the ranges of 0.0001-0.005%, and 0.0015-0.004%, respectively, with respect to the composition.
[0074] Further, it was observed that the combination of dodecanolide and citral used at various concentrations such as 225, 112.5 and 56.25 ug mL"1 of dodecanolide and 100, 50, 12.5 and 6.25 ug mL"1 of citral did not show the synergistic effect in inhibiting the biofilm formed by MRSA, with FIC indices greater than 0.5.
[0075] Henceforth, it can be concluded that the composition having a combination of dodecanolide and citral at 14.0625+25 ug mL"1 and 28.125+25 ug mL"1, were considered as the working compositions of the present disclosure, whereas, composition having a combination of dodecanolide and citral at concentrations such as 225, 112.5 and 56.25 ug mL"1 of dodecanolide and 100, 50, 12.5 and 6.25 ug mL"1 of citral, were considered as the non-working compositions.
(b) Non-antibacterial activity of composition against MRSA [0076] The non-antibacterial activity of synergistic combinations of dodecanolide and citral was confirmed by using Colony Forming Unit (CFU) assay. The working compositions CI having a combination of dodecanolide and citral at 14.0625+25 ug mL"1 and other working composition C2 having a combination of dodecanolide and citral at 28.125 ug/mL+25 ug/mL were added

separately to the tube containing 1 mL of TSBS. Tubes without any treatment and tubes containing TSBS alone were deliberated as control and blank, respectively. All tubes were inoculated with 1% v/v of overnight culture of MRSA and incubated at 37°C for 24 h in a shaker incubator at a speed of 160 rpm. After incubation, the absorbance of the control and treated cells was measured at 600 nm and then cells were harvested by centrifugation (8000 rpm for 10 min) and subsequently suspended in 1 mL of Phosphate Buffered Saline (PBS). The cell suspensions were serially diluted and 100 uL of 10"9 dilution of each sample was spread over the TSBS agar plates. TSBS agar plate spread with 100 uL of PBS was considered as blank. The plates were incubated overnight at 37°C for 24 h. Then, the number of colonies in each plate were counted manually and the graph was plotted. Number of colonies in treated samples were compared with that of control at an optical density of 600 nm. [0077] Figure 4 depicts the representative images of petriplates of CFU assay of the blank, control and the compositions CI and C2 against MRSA biofilm. Figure 5 depicts the assessment of growth of MRSA upon treatment with the compositions CI and C2. As can be seen from the Figure 4, the number of colonies were almost similar in both the control and treated petriplates. Further, it can be observed from Figure 5 that the number of colonies in treated samples comparable with that of control and the optical density at 600nm was also unaffected upon treatment with the compositions CI and C2 on MRSA biofilm. These results altogether substantiated the non-antibacterial nature of synergistic combination of compositions CI and C2 of dodecanolide and citral. Example 3
Biofilm Eradication Assay
[0078] Antibiotics affect the bacterial cells whereas antibiofilm agents prevent the adherence of cells to the substratum. So, for the purpose of potentiating the activity of antibiotic such as rifampicin, the combinatorial approach of antibiotics and the composition of the present disclosure was used to defend the chronic biofilm associated microbial infections. Therefore, the combinatorial effect of rifampicin and the working compositions CI and C2 on pre-formed

MRSA biofilm was evaluated. MRSA biofilm was treated with combination of 5 ug/mL of rifampicin (R5) with CI and C2 individually, for 24 hours. After treatment, the biofilm cells were scrapped off and spread on Tryptone Soya Agar (TSA). As can be observed from Figure 6 that the composition C2 was found to potentiate the biofilm eradication ability of rifampicin. Further, to validate this, live dead staining was performed, and pre-formed MRSA biofilm was visualized under Confocal Laser Scanning Microscope (CLSM). Figure 7 illustrates the images observed under CLSM showing the biofilm eradication ability of rifampicin in the presence of the composition C2 and its comparison with only C2 and only rifampicin. It can be observed from Figure 7 that rifampicin and C2 were ineffective against pre-formed biofilm when used individually whereas combination of C2 and rifampicin greatly disrupted and killed the biofilm cells. [0079] Thus, out of the biofilm eradication assay of the compositions CI and C2 in combination with the antibiotic, the combination of C2 with rifampicin was able to kill the biofilm cells.
[0080] Overall, the combination of the phytochemicals such as dodecanolide and citral in the disclosed weight percentage ranges is essential to have a desired synergistic effect against the biofilm formation in the species of MRSA. The inhibitory effect of dodecanolide against the biofilm formation in the species of MRSA was shown at a concentration of 225 ug mL"1. Similarly, the inhibitory effect of citral against the biofilm formation in the species of MRSA was shown at a concentration of 100 ug mL"1. However, the synergistic combination of dodecanolide and citral showed antibiofilm activity at a low concentration, i.e. 14.0625+25 ug mL"1 and 28.125+25 ug mL"1 with non-anti-bacterial nature. Example 4
Process for preparing the composition of the present disclosure [0081] The process for preparing the composition of the present disclosure comprised the following steps: (a) obtaining 0.0014% dodecanolide; (b) obtaining 0.0025% of citral; (c) contacting dodecanolide and citral to obtain the composition.

Process for preparing the composition having a combination of water phase and oil phase component of the present disclosure
[0082] In the present disclosure, the formulation was prepared by using the active ingredients as disclosed in the composition of the present disclosure. The formulation such as a topical cream or lotion comprised the composition of the present disclosure along with water and oil phase components such as preservative, feel enhancer, neutraliser, humectant, emollient, structurant, chelant, solvent, and combinations thereof. Formulation as disclosed in the present disclosure can be used in a form of a topical cream or lotion. [0083] Water phase components of the present disclosure
1. Any one of the said preservatives such as paraben, gluconolactone, sodium benzoate, chlorobutanol, benzyl alcohol, imidazolidinyl urea, benzalkonium chloride, alpha tocopherol, sodium sulphite, methyl-dibromo glutaronitrile, tea tree essential oil can be used at the range of 0.005% to 0.5%.
2. Any one of the said humectants such as aloe vera powder, arnica extract, algae extract, hydrolyzed baobab protein, coenzyme qlO, hydrolyzed collagen protein, colloidal oatmeal, glycerin, caprylyl glycol, ceramide complex, lacto-ceramide, matrixyl s-6, propylene glycol, rhubarb root extract, hyaluronic acid, hydrolyzed jojoba protein, hydrolyzed keratin protein, sodium PC A can be used at the range of 0.01% to 10%.
3. Any one of the said chelants such as diethylenetriaminepentaacetic acid, tetrasodium ethylenediaminetetraacetate, disodium ethylenediaminetetraacetate, triglycollamic acid, ethane 1-hydroxy-1, 1-diphosphonate, polyphosphates, citric acid can be used at the range of 0.01% to 0.5%.
[0084] Oil phase components of the present disclosure
1. Any one of the said feel enhancers such as Isopropyl myristate, Bis-diglyceryl polyacyladipate-1, butylene glycol dicaprylate/dicaprate, cetearyl isononanoate, decyl oleate, glyceryl oleate, glyceryl ricinoleate,

oleyl erucate, olus oil, alkyl citrate and stearate esters, waxes, essential oils can be used at the range of 0.01% to 25%.
2. Any one of the said neutralizers such as borax, sodium hydroxide, sodium carbonate and alkali extract of coconut husk, triethanol amine can be used at the range of 0.0004% to 0.4%.
3. Any one of the said emollients such as amodimethicone, CI 2-15 alkyl benzoate, cetyl palmitate, isopropyl myristate, jojoba gel, mineral oil, natural gel-wax, octyldodecanol, amodimethicone, cyclodimethicone, cyclomethicone, dimethicone 500, dimethicone satin, isodimethicone copolymer, PEG8, polyisobutene 250, squalane, almond oil, castor oil, grapeseed oil, red raspberry seed oil, cherry kernel oil can be used at the rangeof0.05%to20%.
4. Any one of the said structurants such as rice bran oil, corn oil,
sunflower oil, starch, alginate, carnauba wax, bees wax, berry wax, fruit
wax, silicone-based polymers, acrylate copolymer, cellulose based
polymers can be used at the range of 0.01 to 7%.
[0085] The solvents used in the present disclosure: methanol, ethanol or Dimethyl Sulfoxide (DMSO) and water in the range of 10% to 98%. Overall the components used for preparing the formulation are shown in Table 2 below.

[0086] Table 2 depicts a formulation table comprising the composition of the present disclosure. According to the present disclosure, the formulation was prepared by using the active ingredients i.e. synergistic combinations of dodecanolide (0.0014%) and citral (0.0025%), along with other mentioned ingredients in the desirable quantity.
[0087] The formulation of the synergistic combination of dodecanolide and citral as disclosed in the present disclosure was prepared by the following steps:
1. The water (aqueous) phase was prepared by dissolving the water-soluble components (water phase components) such as sodium benzoate, glycerin and Disodium Ethylenediamine-Tetraacetate (EDTA) in required quantity of water.
2. The aqueous phase was kept in 70°C water bath for 30 minutes and stirred for 15 minutes at 300 rpm until all the components were completely dissolved to obtain the first mixture.
3. In another set, the oil phase components such as isopropyl myri state, triethanolamine, almond oil, and berry wax were weighed in a required quantity, mixed and heated to a temperature of 70°C for 30 minutes and stirred for 30 minutes at 400 rpm to obtain better solubilised second mixture.
4. Then, the first mixture containing the aqueous phase was slowly added to the second mixture of oil phase with moderate agitation and was stirred for 30 minutes at 500 rpm, to obtain the third mixture.

5. The active ingredients of the current disclosure, i.e., dodecanolide and citral were dissolved in methanol at stock concentration of 1%, separately.
6. Dodecanolide and citral composition at their working concentration of 0.0014 % and 0.0025 %, respectively, were added to the third mixture and stirred for 45 minutes at 500 rpm at 35-40°C.
7. The formulation was cooled to room temperature and pH range of the formulation was measured to be 5-6.
8. Then, the formulation was stored at room temperature without direct exposure to sunlight with shelf life in the time period range of 12 to 26 months from the date of preparation.
[0088] Overall, it can be concluded that the presence of the combination of two active ingredients such as dodecanolide and citral in the disclosed weight percentage of 0.0001-0.005% and 0.0015-0.004%, respectively, with respect to the composition is very crucial for arriving at the composition of the present disclosure. Any deviation of the composition from their disclosed weight percentage ranges or absence of any one of the component would not lead to the desired synergistic effect on inhibiting the biofilm activity of MRS A. Advantages of the present disclosure
[0089] The present disclosure discloses a composition comprising dodecanolide and citral, wherein dodecanolide has a weight percentage in a range of 0.0001-0.005%) with respect to the composition, and citral has a weight percentage in a range of 0.0015-0.004% with respect to the composition. The combination of the phytochemicals provides a synergistic effect against the biofilm formation of MRSA species even at a very low concentration. The synergistic combination disclosed in this disclosure also exhibits the non-antibacterial property, i.e., it does not affect the viability of bacterial cells. The combinatorial effect of rifampicin and synergistic combination of dodecanolide and citral disrupts and kill the biofilm cells. Since the phytochemicals such as dodecanolide and citral are considered as Generally recognized as safe (GRAS) compounds, therefore, the composition is non-toxic and harmless. This combinatorial strategy of using

the combination of phytochemicals helps in reducing the probability of developing multidrug resistance. A formulation comprising the composition can be further used in the form of topical application such as anti-biofilm cream, ointment, lotion, paste, gel, or the like. Overall, the present disclosure provides a cost-effective, non-toxic and potential composition exhibiting anti-biofilm activity against MRSA species without developing antibiotic resistance.

1. A composition comprising:
a. dodecanolide; and
b. citral,
wherein dodecanolide has a weight percentage in a range of 0.0001-0.005% with respect to the composition, and citral has a weight percentage in a range of 0.0015-0.004% with respect to the composition.
2. The composition as claimed in claim 1, wherein the composition further comprises at least one water phase component.
3. The composition as claimed in claim 1, wherein the composition further comprises at least one oil phase component.
4. The composition as claimed in claim 1, wherein the composition further comprises a combination of at least one water phase and at least one oil phase component.
5. The composition as claimed in claim 2, wherein the at least one water phase component is selected from a group consisting of preservatives, humectants, chelants, and combinations thereof.
6. The composition as claimed in claim 3, wherein the at least one oil phase component is selected from a group consisting of feel enhancers, neutralizers, emollients, structurants, and combinations thereof.
7. The composition as claimed in claim 5, wherein the preservatives has a weight percentage in a range of 0.005-0.5%) with respect to the composition, humectants has a weight percentage in a range of 0.01-10%) with respect to the composition, chelants has a weight percentage in a range of 0.01-0.5%) with respect to the composition.
8. The composition as claimed in claim 6, wherein the feel enhancers have a weight percentage in range of 0.01-25%) with respect to the composition, neutralizers have a weight percentage in a range of 0.0004-0.4%) with respect to the composition, emollients have a weight percentage in a range of 0.05-20%> with respect to the composition, and

structurants have a weight percentage in a range of 0.01-7% with respect to the composition.
9. The composition as claimed in any one of the claims 1 to 4, wherein the composition exhibits inhibitory activity against biofilm formation.
10. The composition as claimed in claim 9, wherein the biofilm formation is formed by Staphylococcus aureus.
11. The composition as claimed in any one of the claims 1 to 4, wherein the composition is effective for a period of 12 months to 26 months.
12. A process for preparing the composition as claimed in any of the claims 1 to 3, said process:
a. obtaining dodecanolide;
b. obtaining citral;
c. obtaining at least one water phase component or at least one oil
phase component; and
d. contacting dodecanolide and citral with the at least one water
phase component or the at least one oil phase component to
obtain the composition.
13. A process for preparing the composition as claimed in any one of the
claims 1 and 4, said process comprising:
a. heating the at least one water phase component to a temperature
in range of 65-75°C for a time period in a range of 25-35 minutes,
to obtain a heated water phase component, and blending the
heated water phase component at a speed in a range of 200-400
rpm for a time period in a range of 10-20 minutes to obtain a first
mixture;
b. heating the at least one oil phase component at a temperature in a
range of 60-80°C for a time period in a range of 25-35 minutes to
obtain, to obtain a heated oil phase component, and blending the
heated oil phase component at a speed of 300-500 rpm for a time
period in a range of 20-40 minutes to obtain a second mixture;

c. contacting the first mixture and the second mixture at a speed in a
range of 400-600 rpm for a time period in range of 2-40 minutes
to obtain the third mixture; and
d. contacting dodecanolide, citral, the at least one solvent and the
third mixture at a speed in a range of 400-600 rpm for a time
period in a range of 40-50 minutes at a temperature in a range of
35-40°C, to obtain the composition.
14. The process as claimed in any one of the claims 12 to 13, wherein the process further comprises at least one solvent having a weight percentage in a range of 10-98% with respect to the composition.
15. The process as claimed in claim 14, wherein the at least one solvent is selected from a group consisting of water, methanol, ethanol, dimethyl sulfoxide (DMSO), and combinations thereof.